Abstracts Archive - Page 55 of 2425 - ACR Meeting Abstracts

Abstract Number: 0080 • ACR Convergence 2024
Enhanced Cytotoxicity of Aging Associated NKG2C+ CD8+ T Cells in Ankylosing Spondylitis via HLA-B27
Kunhai Tang, Xiaobei Ma, Jian Gao, Feng Qian, Qi Zhu, Jiucun Wang and Jing Liu, Fudan University, Shanghai, China (People's Republic)
Background/Purpose: Ankylosing spondylitis (AS) is an immune-related chronic inflammatory disease characterized by inflammatory pain in the lower back and spinal ankylosing, accompanied by immune system disorders, such…
Abstract Number: 0098 • ACR Convergence 2024
Anti-HSP90α as a Protective Natural Antibody Against Secondary Antiphospholipid Syndrome in Systemic Lupus Erythematosus
Marina Barguil Macedo¹, Jorge Armando Gonzalez-Chapa¹, Anders Bengtsson², Iva Gunnarsson³, Elisabet Svenungsson⁴ and Christian Lood¹, ¹University of Washington, Seattle, WA, ²Lund University, Lund, Sweden, ³Karolinska Institute, Stockholm, Sweden, ⁴Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Heat shock protein 90 alpha (HSP90α) is an epichaperone present ubiquitously inside the cell, whose dimers function as a foldase that helps the correct…
Abstract Number: 0132 • ACR Convergence 2024
Patients with Systemic Autoimmune Rheumatic Diseases Remain at Risk for Hospitalization for COVID-19 Infection in the Omicron Era (2022-2024): A Retrospective Cohort Study
Naomi Patel¹, Andrew King¹, Shruthi Srivatsan¹, Xiaosong Wang², Emily Kowalski³, Kathleen Vanni³, Grace Qian², Jennifer Hanberg³, Katarina Bade³, Alene Saavedra³, Kevin Mueller³, Zachary Williams¹, Colebrook Johnson¹, Madison Negron¹, Jeffrey Sparks⁴ and Zachary Wallace⁵, ¹Massachusetts General Hospital, Boston, MA, ²Brigham and Women’s Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA, ⁵Massachusetts General Hospital, Newton, MA
Background/Purpose: The risk of severe acute COVID-19 infection has substantially decreased since the start of the pandemic. However, the risk of severe acute COVID-19 outcomes…
Abstract Number: 0127 • ACR Convergence 2024
Unsupervised Machine Learning Improves Clinical Stratification and Prognostic Evaluation for Antiphospholipid Syndrome: A Large Cohort Study from China
Chen Chen¹, Ao Zhang², Jianhui Cheng³, Zhongqiang Yao⁴, Juan Meng⁵, Yilu Qin⁶, Qingyi Lu¹, Yufei Li¹, Xiangjun Liu¹, Tianhao Li⁷, Chao Hou⁷, Yundi Tang¹, Hongjiang Liu⁸, Ning Xu¹, Sai Dong¹, Xinxin Li³, Fangmin Xu², Jianping Guo¹ and Chun Li¹, ¹Peking University People's Hospital, Beijing, China, ²Beijing University of Posts and Telecommunications, Beijing, China, ³State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, China (People's Republic), ⁴Peking University Third Hospital, Beijing, China, ⁵Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing, China, ⁶Affiliated Xinxiang Central Hospital of Xinxiang Medical University, Xinxiang, China (People's Republic), ⁷Peking University Health Science Center, Beijing, China, ⁸West China Hospital, Sichuan University, Chengdu, China (People's Republic)
Background/Purpose: Antiphospholipid syndrome (APS) is a complex disease characterized by the presence of anti-phospholipid antibodies (aPLs). Its significant clinical heterogeneity brings clinical and therapeutical challenges.…
Abstract Number: 0083 • ACR Convergence 2024
Culturing and Comparative Analysis of Small Intestinal Organoids from SKG and MIFKO-SKG Mice
Mariia Korshko¹, Shaghayegh Foroozan Boroojeni² and Nigil Haroon³, ¹University Health Network, Toronto, ON, Canada, ²UHN, Toronto, Canada, ³Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada
Background/Purpose: Axial Spondyloarthritis (AxSpA) is a chronic inflammatory disease affecting both the joints and gut, with 60% of patients showing microscopic and 10% overt IBD…
Abstract Number: 0194 • ACR Convergence 2024
Machine Learning Methods to Predict Cardiovascular Risk in Hispanic Patients with Systemic Lupus Erythematosus
Ariana Gonzalez-Melendez¹, Jeann Hernandez-Franco², Dylan Cedres-Rivera³ and Abiel Roche-Lima³, ¹University of Puerto Rico - Medical Science Campus, Guaynabo, PR, ²University of Puerto Rico, San Juan, PR, Puerto Rico, ³Center for Collaborative Research in Health Disparities, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico, San Juan, PR, Puerto Rico
Background/Purpose: The most common cause of death among patients with systemic lupus erythematosus (SLE) is cardiovascular disease (CVD). Previous studies have performed cardiovascular risk stratification;…
Abstract Number: 0114 • ACR Convergence 2024
Rare Germline Variants in Complement Regulatory Genes in Antiphospholipid Antibody Positive Patients: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Cécile Yelnik¹, shruti chaturvedi², Julien Labreuche³, Xiang-Zuo Pan², H Michael Belmont⁴, Nina Kello⁵, Paul Fortin⁶, David Branch⁷, Yu Zuo⁸, Rohan Willis⁹, Robert Brodsky², Jane Salmon¹⁰, Maria Laura Bertolaccini¹¹, Hannah Cohen¹², Michelle Petri¹³ and Doruk Erkan¹⁰, and on behalf of APS ACTION, ¹lille university, Lille, France, ²John Hopkins University, Baltimore, MD, ³Lille University Hospital, Lille, France, ⁴NYU Langone Health, New York, NY, ⁵Northwell Health, Brooklyn, NY, ⁶Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ⁷University of Utah and Intermountain Healthcare, Salt Lake City, UT, ⁸University of Michigan, Ann Arbor, MI, ⁹University of Texas Medical Branch, Galveston, TX, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹King's College London, London, United Kingdom, ¹²University College London Hospitals NHS Foundation Trust, London, United Kingdom, ¹³Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: We previously reported that markers of complement activation, specifically elevated C4d levels and positive modified HAM (mHAM) test, are associated with a higher risk…
Abstract Number: 0146 • ACR Convergence 2024
Enhancing Pre-Biologic Response Modifier Screening for Coccidioidomycosis in Endemic Regions
Bashar Tanous¹, SRIKAR SAMA², Nidaa Rasheed³ and Candice Reyes⁴, ¹UCSF Fresno, Fresno, ²University of California San Francisco Fresno, Fresno, CA, ³UCSF Fresno, Fresno, CA, ⁴VACCHCS, Fresno, CA
Background/Purpose: Biologic response modifiers (BRMs), also known as "biologics," have become essential tools in treating various chronic inflammatory conditions. However, the immunosuppression caused by these agents…
Abstract Number: 0171 • ACR Convergence 2024
Associations Between Discrimination Experiences and Patient-Reported Outcomes Among Asian Individuals with Systemic Lupus Erythematosus (SLE)
Patti Katz¹, JoonSuk Park², Kamil Barbour³, Kurt Greenlund³, Maria Dall'Era⁴ and Jinoos Yazdany², ¹UCSF, San Rafael, CA, ²University of California San Francisco, San Francisco, CA, ³CDC, Alpharetta, GA, ⁴UCSF, Corte Madera, CA
Background/Purpose: Discrimination experiences have been linked to poor outcomes among Black individuals with SLE.1 Among Asian adults in the general US population, discrimination has been…
Abstract Number: 0118 • ACR Convergence 2024
Performance of the 2023 ACR/EULAR Classification Criteria for Antiphospholipid Syndrome in a Mexican Cohort
Erik Cimé-Aké¹, Gabriela Hernández-Molina², Amaya Llorente-Chávez³ and Eduardo Martin Nares², ¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Immunology and Rheumatology Department, Mexico City, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Hematology Department, Mexico City, Distrito Federal, Mexico
Background/Purpose: The 2023 ACR/EULAR classification criteria (2023 AECC) for antiphospholipid syndrome (APS) were recently published. The new criteria require an entry criterion and employe a…
Abstract Number: 0010 • ACR Convergence 2024
Precision Editing of Cyclophilin a to Engineer Cyclosporine- and Voclosporin- Resistant Human CAR-T Cells
Holly Wobma¹, Francesca Alvarez-Calderon², Jiayi Dong², Alexandre Albanese², Kayleigh Omdahl², Rene Bermea³, Gillian Selig⁴, Marlana Winschel², Elisa Rojas Palato², Katherine Michaelis¹, Xianliang Rui², Bruce Blazar⁵, Susan Prockop², Victor Tkachev³, Ulrike Gerdemann² and Leslie Kean², ¹Division of Immunology, Boston Children's Hospital, Boston, MA, ²Division of Hematology-Oncology, Boston Children's Hospital, Boston, MA, ³Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, ⁴Harvard College, Boston, MA, ⁵Division of Pediatric Blood and Marrow Transplantation & Cellular Therapy, University of Minnesota, Minneapolis, MN
Background/Purpose: With exponential demand for chimeric antigen receptor (CAR) therapies for autoimmune disease, allogeneic options will be essential. Advantages include use of healthy donor cells,…
Abstract Number: 0153 • ACR Convergence 2024
Frequencies and Rates of All-Cause Emergency Visits and Hospitalizations in Persons with Inflammatory Arthritis Conditions and Gout: A Systematic Review
Kara Irwin, Ran Huo, Claire Barber and Cheryl Barnabe, University of Calgary, Calgary, AB, Canada
Background/Purpose: Despite advances in the management of inflammatory arthritis (IA) and gout, many patients still access acute care services. This may be related to their…
Abstract Number: 0158 • ACR Convergence 2024
Rheumatoid Arthritis Testing Patterns by Physicians and Advanced Practice Providers from a National Commercial Laboratory, 2014 – 2023
Karis Lee¹, Min Kyung Lee², David Alfego³, Kristen Clark⁴ and Stanley Naides⁵, ¹Labcorp, Orlando, FL, ²Labcorp, San Diego, CA, ³Labcorp, Carlsbad, CA, ⁴Labcorp, Raleigh, NC, ⁵Labcorp, Dana Point, CA
Background/Purpose: With the commercialization of new diagnostic and monitoring tests for rheumatoid arthritis (RA) and an increasing number of advanced practice providers (APPs) in the…
Abstract Number: 0161 • ACR Convergence 2024
Cross Country Burden of Osteoarthritis in Latin America and Caribbean from 1990-2021: A Comparative and Consistent Benchmarking Analysis for the Global Burden of Disease Study 2022
malay rathod¹, Eva Kalra², Rafael Sanchez-Dopazo,³, Janmay Vala⁴, Saif Syed⁵, Akhilesh Sharma⁶, Ashwinikumar Shandilya⁷, Asmita Gera⁸, Mohit Lakkimsetti⁹, Juhi Patel¹⁰, VISHRANT AMIN¹¹ and Hardik Desai¹², ¹Monmouth Medical Center, Rutgers University, Ewing, NJ, ²Trident Medical Cente, Charleston, SC, ³Larkin Community Hospital Palm Springs Campus, Hialeah, FL, ⁴Terna Medical College, Navi Mumbai, Maharashtra, India, ⁵Royal college of Surgeons,Dublin,Ireland, Dublin, Dublin, Ireland, ⁶Adesh Institute of Medical Sciences and Research, Bhatinda, India, ⁷Rural Medical college. Pravara institute of medical sciences., Ahmednagar, India, ⁸Tianjin medical University, Tianjin, China, Tianjin, Tianjin, China (People's Republic), ⁹Mamata Medical College,Khammam, Khammam, Telangana, India, ¹⁰GMERS MEDICAL COLLEGE VALSAD, 382330, Gujarat, India, ¹¹GMERS MEDICAL COLLEGE VALSAD, Ahmedabad, India, ¹²Gujarat Adani Institute of Medical Sciences, Bhuj, India
Background/Purpose: Osteoarthritis (OA) poses a significant and escalating health challenge across Latin America and the Caribbean (LAC), driven by demographic shifts, lifestyle factors, and varying…
Abstract Number: 0068 • ACR Convergence 2024
Enhanced Expression of GPR65 in Inflammatory Sites and Bone Formation Regions in Ankylosing Spondylitis: Evidence from ScRNA-seq Analysis
Yong-Wook Park¹, Ki-Jeong Park², Sungsin Jo³, Tae-Hwan Kim⁴ and Tae-Jong Kim¹, ¹Department of Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea, ²Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea, ³Hanyang University Institute for Rheumatology Research, Seoul, Republic of Korea, ⁴Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily affecting the axial skeleton. T helper 17 (Th17) cells play a pivotal role in the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].